Category

Archives

Alvocidib is a cyclin dependent kinase inhibitor under clinical development for the treatment

Lipopolysaccharide is the primary constituent of the outer leaflet of the outer membrane of Gram-negative bacteria . In addition to being the major surface molecule in Gram-negative bacteria, Alvocidib is also considered a major pathogenic factor. Lipid A, also referred to as endotoxin, is the hydrophobic membrane anchor of LPS and is known to be a potent inducer of the host innate immune system . Structurally, lipid A is characterized as a phosphoglycolipid defined by a conserved diglucosamine disaccharide with structural variations occurring by fatty acid position and identity, phosphorylation, and additional monosaccharide modification. Alteration of lipid A structure greatly affects the bacterium's virulence and can occur via a variety of environmental stimuli including divalent ion concentration, temperature, and other growth conditions . The phosphorylation pattern of lipid A has been shown to be important for its biological activity. For example, removal of a phosphate group has been shown to substantially reduce lipid A toxicity and interleukin-1 induction capacity . By contrast, masking of lipid A phosphate groups has been shown to affect bacterial resistance to host Anastrozole cationic antimicrobial peptides .
The biochemical effects of phosphate groups in lipid A have been attributed to their negative charge that affects recognition by the Toll-like receptor 4 and further LPS-induced signaling in the host immune response to bacterial infection . Furthermore, monosaccharide modification to lipid A is thought to occur via an ester linkage with the phosphate substituents. The biosynthesis of axitinib lipid A, as characterized in Escherichia coli, involves LPS intermediates that have a 1-position pyrophosphate and a 4_-position monophosphate . An inner membrane enzyme has been recently identified that transfers a phosphate group to the lipid A moiety to form the 1-position pyrophosphate structure . However, lipid A is commonly described as Bosutinib bisphosphorylated with monophosphate attachment at the 1- and 4_-positions of the glucosamine dimer backbone or monophosphorylated with phosphate attachment at either the 1- or 4_-position. We intend to demonstrate that several Gram-negative bacteria produce diphosphorylated lipid A that retains the pyrophosphate substituent. This finding is important for further studies of biochemical modifications of LPS that involve yet unknown mechanisms .
Our particular emphasis is centered on Yersinia pestis , the causative agent of the plague, which is a highly invasive and often lethal Gram-negative pathogen that is transmitted to the mammalian host by either fleabite or inhalation of an infectious droplet . Because of its potential use as a bioterrorism agent, Yp has been classified by the Center for Disease Control and Prevention as a Class A select agent. Transmission from the flea vector to the mammalian host induces temperature-dependent structural modification of Yp lipid A . At the mammalian host temperature of 37C, the primary structure of lipid A consists of a linked diglucosamine disaccharide with two phosphate moieties at the 1 and 4 positions, amide-linked 3-hydroxymyristic acids at the 2- and 2_-positions, and ester-linked 3-hydroxymyristic acids at the 3- and 3_-positions . However, at a temperature typical of the flea vector , the primary lipid A structure is hexa-acylated. The additional fatty acids, palmitoleic acid and lauric acid , are thought to be ester-linked via the 3-hydroxy position of the 3 and 3_ fatty acids, respectively, to form acyloxyacyl groups . Furthermore, Yp lipid A from both Apoptosis temperature variants has been reported to contain modifications of aminoarabinose and phosphoethanolamine . Despite extensive research, ambiguity remains to date as to the exact location of the acyloxyacyl fatty acids, phosphate moieties, and other modifications. Diphosphorylated lipid A is generally presumed to be phosphorylated at the 1- and 4_-positions. Our initial analysis of Yp lipid A grown at 37C and 21C suggested that several diphosphorylated lipid A structures from these two growth conditions were pyro- phosphorylated rather than bisphosphorylated.

Related Products

Cat.No. Product Name Information
S1230 Flavopiridol (Alvocidib) Flavopiridol (Alvocidib) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4, CDK6, and CDK9 with IC50 values in the 20-100 nM range. It is more selective for CDK1, 2, 4, 6, 9 versus CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol induces autophagy and ER stress. Flavopiridol blocks HIV-1 replication. Phase 1/2.

Related Targets

CDK